BioLineRX
BLRX
28 hedge funds and large institutions have $28.5M invested in BioLineRX in 2017 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
8% more funds holding
Funds holding: 26 → 28 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.04% less ownership
Funds ownership: 0.1% → 0.06% (-0.04%)
18% less capital invested
Capital invested by funds: $34.9M → $28.5M (-$6.4M)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$149K |
| 2 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
+$94.1K |
| 3 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
+$64.8K |
| 4 |
Morgan Stanley
New York
|
+$31.9K |
| 5 |
VanEck Associates
New York
|
+$31.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.17M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.11M |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$168K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$165K |
| 5 |
Renaissance Technologies
New York
|
-$126K |
BLRX Hedge Fund Activity: Q2 2017 in Review
28 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q2 2017, worth a combined $28.5M — down 18% from $34.9M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new BLRX positions and 3 closed out — a net gain of 2 holders — while 3 added to existing stakes and 5 trimmed.
The largest buyer was Deutsche Bank, adding an estimated $149K. The largest seller was Alyeska Investment Group, cutting an estimated $1.17M.
- 28 institutional investors held BioLineRX (BLRX) as of Q2 2017, up from 26 in Q1 2017.
- Funds reported $28.5M of BioLineRX stock for Q2 2017, down 18% quarter-over-quarter.
- 5 funds opened new BioLineRX positions in Q2 2017 and 3 closed out, a net change of +2 holders.
- The largest BioLineRX buyer in Q2 2017 was Deutsche Bank, an estimated $149K added.
- The largest BioLineRX seller in Q2 2017 was Alyeska Investment Group, an estimated $1.17M sold.
Based on aggregated 13F filings for Q2 2017.